The global oligonucleotide synthesis market size was estimated at USD 3.29 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 13.22% by 2030. The decreasing prices of sequencing have led to increasing demand for custom-made nucleotides for a preferred sequencing across genetic testing, research, forensics applications, and drug development. This has further boosted the demand for oligonucleotide synthesis. The COVID-19 pandemic has affected every market globally and there has been a surge in the demand for efficient treatment against COVID-19. Healthcare providers and pharmaceutical companies are working on discovering the potential usage of oligonucleotides to contain the spread of virus. For instance, the Innovative Genomics Institute stated that they are working towards the development of new treatments for patients suffering from COVID-19 with acute respiratory symptoms by using antisense oligonucleotide therapeutics.
Oligonucleotide therapeutics holds immense potential for treatment of chronic conditions such as cancers, cardiovascular diseases, and retinal disorders. Emerging novel applications of oligo sequences in various fields of biotechnology are anticipated to boost market growth. Demand for molecular diagnostics in precision care is one of the significant emerging fields of application for oligonucleotide synthesis.
Introduction of advanced techniques such as CRISPR and high-throughput sequencing for gene expression analysis has simplified the genetic screening and modification of genomes. Such innovations are observed to influence the demand for oligonucleotide synthesis. Manufacturers invest in development of technology to enable production of long Oligonucleotide with higher precision and better yield to cater the growing need for custom oligos.
Availability of regulatory environment that supports the progress of genomics is the key factor contributing to the large revenue share of North America. Local presence of key players with a well-established distribution network across the region further strengthens the oligonucleotide synthesis market.
The services segment held the highest market share of 30% in 2022 and is expected to witness the highest growth during the forecast period. Certain factors such as growing use of molecular diagnostic tests coupled with the higher adoption of oligonucleotide therapeutics are expected to contribute to market growth. Moreover, key players are also involved in broadening their offerings by entering new markets or by the acquisition of service providers in different countries.
Furthermore, the oligonucleotide segment is anticipated to project considerable growth in the coming years. With the increase in the number of genomic studies being carried out, such as gene expression analysis and genetic testing, can be attributed to a substantial revenue share. In addition, the introduction of biochips (DNA chips) for parallel analysis of a large number of clinical samples is anticipated to contribute considerably to the markets’ revenue. With growing usage of antisense oligonucleotide in clinical trials for various conditions such as cancer, cardiac disorders, and ocular dysfunctions, the segment is anticipated to witness lucrative growth in the near future. Increasing use of technologies such as PCR, sequencing, and DNA microarrays for genetic testing and biological sample analysis further boosts the revenue growth.
The PCR primers segment registered the highest market share of 23.4% in 2022. Primers are the most widely used oligonucleotide in PCR. They are part of sequences complementary to the 5’ end of the targeted sequence and are used for sequencing or amplification application. The adoption of primers for gene sequencing experiments is increasing. Their use in fluorescent detection and target amplification has led to the development of various primer designs with different probe- and primer-based detection chemistries. With advances in technology, PCR has evolved and has resulted into RT-PCR, qPCR, and digital PCR. PCR assays and panels are designed for detecting and measuring gene expression. Need for primers to suit the application of these enhanced systems for uses such as accurate quantification of gene expression is anticipated to fuel market growth.
PCR assays and panels segment is anticipated to witness lucrative CAGR of 13.65% during 2023-2030. PCR panels and assays are designed and developed for the detection and measurement of gene expressions in biologically related genes. These assays are preconfigured to increase the range of canonical pathways, signaling, diseases, and other cellular processes. For instance, PCR assays for glycogen metabolism genes, IL-12 signaling pathways, and protein groups such as growth factors are easily available commercially.
The academic research institutes segment held the highest market share of 42.9% in 2022 owing to the extensive genomic research being conducted by universities and academic research institutes either in collaboration with private investors or with government support. Huge investment by developed countries for genomic research to compete and lead the global market has extended financial support to academic research.
Furthermore, the pharmaceuticals and biotechnology companies’ segment is projected to witness significant CAGR of 13.3% during 2023-2030. Pharmaceutical companies generate significant demand for oligonucleotide synthesis for the development of oligonucleotide-based drugs along with their use in target screening and identification. High adoption of oligo sequences for investigating their clinical pharmacology, study drug-drug interaction, immunogenicity, and renal impairment has made a significant contribution to the segment growth. Advances in oligonucleotide therapeutics with their success in initial phases of clinical trials can be attributed to the segment growth.
North America dominated the global market with a revenue share of over 32.3% in 2022. The large share is mainly attributed to the presence of a large number of companies as well as research institutes creating high demand for oligonucleotides. For instance, in April 2021, DNAScript collaborated with Moderna along with a USD 5 million grant from the U.S. Defense Advanced Research Projects Agency. This collaboration was intended for the development of a prototype for robust manufacturing of therapeutics and vaccines as part of the global nucleic acids on-demand program.
Asia Pacific is poised to witness the fastest CAGR of 14.91% during 2023-2030. This is due to the growing interest of key players in emerging markets in gaining higher profits. Players have adopted various strategies such as acquisitions, collaborations, and distribution agreements to gain higher market share by increasing their revenue generation.
Groundbreaking innovations such as CRISPR and NGS in biotechnology have led to developments in genomics as well as the healthcare sector. Increase in use of oligonucleotides in therapeutics and molecular diagnostics drives its demand in developed countries. In addition, adoption of advanced diagnostic tools and focus on precision medicine in developed countries also drives the demand for oligonucleotide synthesis.
Key entities in the market are undertaking several strategic initiatives such as new product launches, partnerships, geographical expansion, strategic collaborations, mergers and acquisitions to strengthen the market presence. For instance, in February 2023, CPI, Novartis, AstraZeneca and the University of Manchester announced a partnership to expand patient access to life-saving oligonucleotide therapeutics. This partnership is aimed to revolutionize oligonucleotide-based therapeutics in the treatment of various life-threatening diseases. Some of the prominent players in the oligonucleotide synthesis market include:
Thermo Fisher Scientific, Inc.
Merck & Co., Inc.
GE Healthcare
Dharmacon Inc.
Agilent Technologies
Bio-synthesis
Kaneka Eurogentec S.A
Integrated DNA Technologies, Inc.
BioAutomation
Biolegio
Twist Bioscience
Report Attribute |
Details |
Market size value in 2023 |
USD 3.70 billion |
Revenue forecast in 2030 |
USD 8.83 billion |
Growth rate |
CAGR of 13.22% from 2023 to 2030 |
Base year for estimation |
2022 |
Historical data |
2018 - 2021 |
Forecast period |
2023 - 2030 |
Quantitative units |
Revenue in USD million and CAGR from 2023 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, application, end-user, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Mexico, Argentina; South Africa; Saudi Arabia, UAE; Kuwait |
Key companies profiled |
Thermo Fisher Scientific, Inc.; Merck & Co., Inc.; GE Healthcare; Dharmacon Inc.; Agilent Technologies; Bio-synthesis; Kaneka Eurogentec S.A.; Integrated DNA Technologies, Inc.; BioAutomation; Biolegio; Twist Bioscience |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the global oligonucleotide synthesis market report on the basis of product, application, end-user, and region.
Product Outlook (Revenue, USD Million, 2018 - 2030)
Oligonucleotides
Oligonucleotides, By Product Type
Column-based Oligos
Array-based Oligos
Oligonucleotides, By Nucleic Acid Type
DNA
RNA
Equipment/Synthesizer
Reagents
Services
Oligo Synthesis
25 nmol
50 nmol
200 nmol
1000 nmol
10,000 nmol
Purification
Modification
Application Outlook (Revenue, USD Million, 2018 - 2030)
PCR Primers
PCR Assays and Panels
Sequencing
DNA Microarrays
Fluorescence In Situ Hybridization (FISH)
Antisense Oligonucleotides
Other Applications
End-use Outlook (Revenue, USD Million, 2018 - 2030)
Academic Research Institutes
Diagnostic Laboratories
Pharmaceutical - Biotechnology Companies
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
South Korea
Thailand
Australia
Latin America
Brazil
Mexico
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
b. The global oligonucleotide synthesis market size was estimated at USD 3.29 billion in 2022 and is expected to reach USD 3.70 billion in 2023.
b. The global oligonucleotide synthesis market is expected to grow at a compound annual growth rate of 13.22% from 2023 to 2030 to reach USD 8.83 billion by 2030.
b. Services dominated the oligonucleotide synthesis market with a share of 30.00% in 2022. This is attributable to the increasing demand for oligonucleotides in precision medicine.
b. Some key players operating in the oligonucleotide synthesis market include LGC Biosearch Technologies; GE Healthcare, Integrated DNA Technologies, BioAutomation; Inc.; Agilent Technologies; Dharmacon Inc.; and Gene Scripts
b. Key factors that are driving the oligonucleotide synthesis market growth include the declining cost of sequencing, rising demand for custom-made nucleotides, and rising investments in genetic research.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.